Press

Filament Health Corp. To List on Nasdaq Through Business Combination With Jupiter Acquisition Corporation

Jul 20 • 6 min read

Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical‐stage natural psychedelic drug development company, and Jupiter Acquisition Corporation (NASDAQ:JAQC) (“Jupiter“), a special purpose acquisition company formed for the purpose of acquiring or merging with one of more businesses, today announced they have entered into a definitive agreement, dated July 18, 2023, for a…

Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201

Jul 20 • 3 min read

FSD Pharma Inc. (NASDAQ: HUGE / CSE: HUGE / FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today announces that the Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its…

Mushrooms Inc. CEO, Kimberly Carlson, Discusses Exciting Potential of Industrial Mushroom Industry on Psychedelic Spotlight Podcast

Jul 20 • 3 min read

Mushrooms Inc. (OTC: MSRM) is pleased to announce that its CEO, Kimberly Carlson, recently appeared on the esteemed Psychedelic Spotlight Podcast to discuss the exciting potential of the industrial mushroom industry. As the first company trading on the US stock market focused on the industrial side of mushrooms, Mushrooms Inc. is leading the way in…

Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Jul 20 • 5 min read

Bright Minds Biosciences Inc. (CSE:DRUG / NASDAQ:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders and refractory epilepsy, today announced the successful completion of its three-part Phase 1 study of BMB-101. The study, conducted in Adelaide, Australia, by CMAX Clinical Research, a clinical trial center specializing in a…

PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney

Jul 20 • 3 min read

PharmAla Biotech Holdings Inc.(CSE: MDMA / OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is thrilled that – following pre-submission meetings held in Q1 of 2023 – it has received written guidance from the UK’s Medicines and Healthcare products Regulatory Agency’s (MHRA). The guidance constitutes,…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435